Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
This clinical trial update reports enrollment-by-invitation for a study evaluating brain stimulation equipment under a remote viewing effect…
-
FDA approval · 2024-07-11FDA Approved: PREGABALIN — Supplemental Application (ScieGen Pharmaceuticals, Inc)
FDA approved ScieGen Pharmaceuticals' generic pregabalin product through an abbreviated new drug application.
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Virtual Reality for Generalized Anxiety Disorders [NA]
A ClinicalTrials.gov update describes a study investigating virtual reality for Generalized Anxiety Disorder, with no phase or status detail…
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants [Phase 1]
This report covers completion of a Phase 1 trial evaluating adverse events and pharmacokinetics of ABBV-932 oral capsules in healthy adult p…
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: Empower Neuromodulation System - Pilot Study for Anxiety Treatment [NA]
A pilot trial evaluating the Empower Neuromodulation System for generalized anxiety disorder has been terminated, with results posted (as of…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2024-06-12FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for PAROXETINE HYDROCHLORIDE submitted by Zydus Lifesciences Limited, resulting in changes to the pr…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: The MOTIVE (Multiparas Overcoming Childbirth Fear Through Intervention and Empowerement) Feasibility Trial [NA]
The MOTIVE feasibility trial for multiparas addressing fear of childbirth through intervention has completed, evaluating intervention strate…
-
FDA approval · 2024-06-06FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' Venlafaxine hydrochloride as an original-application generic (ANDA 217767). Venlafaxine HCl is indicat…
-
FDA approval · 2024-06-05FDA Approved: PREGABALIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approves the supplemental ANDA for pregabalin from Aurobindo Pharma Limited, enabling the marketing of a generic pregabalin product in t…
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: An Idiographic Examination of Treatment Mechanisms in Emotion Regulation Therapy [NA]
An ongoing clinical trial is examining treatment mechanisms of Emotion Regulation Therapy for rumination and worry; the study status is ACTI…
-
FDA approval · 2024-05-30FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' supplemental application for escitalopram oxalate, enabling a generic version to be marketed.
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: Digital Data in Mental Health Therapy [NA]
A completed clinical trial from the University of Pennsylvania evaluating digital data in mental health therapy for depressive symptoms and …
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety [NA]
This study has completed a pragmatic trial evaluating collaborative care for depression or anxiety in cardiac inpatients. It targets patient…
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: Clinical Trial of a Group Self-management Support Program for Anxiety Disorders [NA]
The trial is active but not recruiting for a group self-management support program targeting anxiety disorders, with listed conditions inclu…
-
CLINICAL_TRIALS withdrawal · 2024-05-08Clinical Trial Update: Cognitive Behavioral Therapy (CBT) for Late Life Anxiety [NA]
A clinical trial evaluating Cognitive Behavioral Therapy for Generalized Anxiety Disorder in older adults has been withdrawn.
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: Internet-delivered Cognitive Behavioral Treatment of Depression and Anxiety in Latin American College Students [NA]
A clinical trial update on internet-delivered cognitive behavioral therapy for depression and anxiety among Latin American college students.…
-
FDA approval · 2024-04-19FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Lexapro (escitalopram) submitted by Allergan, Inc., advancing a labeling action for the product.
-
FDA approval · 2024-04-15FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for escitalopram oxalate from Amneal Pharmaceuticals LLC, approving a generic version of escital…
-
FDA approval · 2024-04-11FDA Approved: ALPRAZOLAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for alprazolam submitted by Aurobindo Pharma Limited under an ANDA. This action indicates approval o…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response [NA]
A completed clinical trial investigating a multi-level predictor for therapy response in generalized anxiety disorder; results posted in 202…
-
FDA approval · 2024-03-21FDA Approved: ESCITALOPRAM ORAL SOLUTION — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for escitalopram oral solution from Chartwell RX, LLC, recognizing a generic formulation.
-
FDA approval · 2024-03-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Camber Pharmaceuticals, approving a new supplement to an existing…
-
FDA approval · 2024-03-15FDA Approved: ALPRAZOLAM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal Pharmaceuticals LLC's supplemental application for Alprazolam (generic) under ANDA078387, signaling a supplemental appro…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder. [Phase 3]
Phase 3 trial investigating toludesvenlafaxine hydrochloride sustained-release tablets for generalized anxiety disorder is currently recruit…
-
FDA approval · 2024-03-08FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for escitalopram oxalate (escitalopram) by Sun Pharmaceutical Industries, enabling marketing of the …